US DRUG CO'S ILLEGAL CONDUCT POLICY CHECK
An investigation into how brand name drug manufacturers address illegal conduct by employees that could jeopardize the safety and efficacy of drugs or undermine the Food and Drug Administration's efforts to regulate drugs is being undertaken by House Energy & Commerce oversight and investigations subcommittee chairman John Dingell.
Rep Dingell has asked for help in this matter from the US Pharmaceutical Manufacturers Association, and the PMA has sent his letter to member companies urging them to respond.
According to the PMA Newsletter, the Association has not objected to the Dingell legislation, but it is concerned about the Senate amendments, which extend individual debarment to research-based company employees.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze